Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture

Ya-Nan Zhang; Qiu-Yan Zhang; Xiao-Dan Li; Jin Xiong; Shu-Qi Xiao; Zhen Wang; Zhe-Rui Zhang; Cheng-Lin Deng; Xing-Lou Yang; Hong-Ping Wei; Zhi-Ming Yuan; Han-Qing Ye; Bo Zhang

doi:10.1080/22221751.2020.1772676

Emerging Microbes and Infections (Jan 2020)

Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture

Ya-Nan Zhang,
Qiu-Yan Zhang,
Xiao-Dan Li,
Jin Xiong,
Shu-Qi Xiao,
Zhen Wang,
Zhe-Rui Zhang,
Cheng-Lin Deng,
Xing-Lou Yang,
Hong-Ping Wei,
Zhi-Ming Yuan,
Han-Qing Ye,
Bo Zhang

Affiliations

Ya-Nan Zhang: Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of China
Qiu-Yan Zhang: The Joint Center of Translational Precision Medicine, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou, People’s Republic of China
Xiao-Dan Li: Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of China
Jin Xiong: Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of China
Shu-Qi Xiao: Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of China
Zhen Wang: Drug Discovery Center for Infectious Disease, Nankai University, Tianjin, People’s Republic of China
Zhe-Rui Zhang: Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of China
Cheng-Lin Deng: Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of China
Xing-Lou Yang: Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of China
Hong-Ping Wei: Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of China
Zhi-Ming Yuan: Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of China
Han-Qing Ye: Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of China
Bo Zhang: Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of China

DOI: https://doi.org/10.1080/22221751.2020.1772676
Journal volume & issue: Vol. 9, no. 1
pp. 1170 – 1173

Abstract

Read online

ABSTRACTThe emerging SARS-CoV-2 infection associated with the outbreak of viral pneumonia in China is ongoing worldwide. There are no approved antiviral therapies to treat this viral disease. Here we examined the antiviral abilities of three broad-spectrum antiviral compounds gemcitabine, lycorine and oxysophoridine against SARS-CoV-2 in cell culture. We found that all three tested compounds inhibited viral replication in Vero-E6 cells at noncytotoxic concentrations. The antiviral effect of gemcitabine was suppressed efficiently by the cytidine nucleosides. Additionally, combination of gemcitabine with oxysophoridine had an additive antiviral effect against SARS-CoV-2. Our results demonstrate that broad-spectrum antiviral compounds may have a priority for the screening of antiviral compounds against newly emerging viruses to control viral infection.

Published in Emerging Microbes and Infections

ISSN: 2222-1751 (Online)
Publisher: Taylor & Francis Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Infectious and parasitic diseases; Science: Microbiology
Website: https://www.tandfonline.com/journals/temi

About the journal

Abstract

Keywords